ArticleNorthern clinics of Istanbul2025
The predictive power of albumin-based composite indicators for mortality in patients with aspiration pneumonia.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe incidence of aspiration pneumonia (AP) is rising due to an increasing population with chronic conditions. This study investigates the association between albumin-based composite indicators-blood urea nitrogen/albumin (B/A), lactate dehydrogenase/albumin (L/A), and C-reactive protein/albumin (C/A) ratios-and AP-related mortality.
methodsIn this retrospective study, adult patients diagnosed with AP between 2022 and 2023 were analyzed. Patients' demographics, clinical data, and lab results were recorded. Albumin-based composite indicators were calculated, and outcomes were observed up to 28 days post-admission, categorizing patients as survivors or non-survivors.
resultsThe study involved 67 patients, with a median age of 80. The 28-day mortality rate was 38.8% (n=26). There were no substantial demographic or clinical differences between survivors and non-survivors (p>0.05). However, non-survivors exhibited notably lower serum albumin levels (p>0.001). Additionally, B/A and C/A ratios were significantly higher in non-survivors (p<0.05). B/A ratios above 1.03 and C/A ratios above 6.15 correlated significantly with mortality (p=0.023 and p=0.026).
conclusionThe results indicate that lower serum albumin levels and higher B/A and C/A ratios are significantly linked to AP-induced mortality. These albumin-based indicators may serve as useful markers for early risk assessment and outcome prediction in AP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.